Velcan Holdings: Convening Notice of the Ordinary Annual General Meeting to be Held on June 25, 2025
Luxembourg, May 23, 2025
VELCAN HOLDINGS: CONVENING NOTICE OF THE ORDINARY ANNUAL GENERAL MEETING TO BE HELD ON JUNE 25, 2025
VELCAN HOLDINGS announces to the shareholders of the Company that the Ordinary Annual General Meeting will be held on Wednesday, June 25, 2025, at 11 a.m, in the offices of the law firm Tabery & Wauthier, 10 rue Pierre d'Aspelt, L‐1142 Luxembourg, in order to vote mainly on the approval of the 2024 condensed non-audited consolidated financial statements and of the 2024 audited statutory financial statements;
All required information and related documents will be available for downloading on the Company's website on May 23, 2025:
Convening notice of the Ordinary Annual General Meeting;
Board of Directors' report on the resolutions proposed to the General Meeting;
Text of the proposed resolutions;
Single participation form.
The annual management report and the audit report are available online since April 29, 2025.
The Board of Directors invites the shareholders to consult the following page:http://www.velcan.lu/investors/reports-accounts/
* * *
Investors Relations Contact investor@velcan.luVelcan Holdings is an investment holding company founded in 2005, managing a global portfolio of participations and investments.
The company was launched more than 15 years ago by its reference shareholder LHP SA, owned by Velcan Holdings' management team.
Velcan Holdings is listed on the unregulated Euro MTF Stock Market in Luxembourg (Ticker VLCN/ISIN FR0010245803). Velcan Holdings never performed any Public Offer as understood under Directive 2003/71/CE of the European Parliament and Council.This press release contains prospective information about the potential of the projects in progress and/or of the projects of which the development has begun. This information constitutes objectives attached to projects and shall not be construed as direct or indirect net income forecast of the concerned year. Reader's attention is also drawn on the fact that the performance of these objectives depends on future circumstances and that it could be affected and/or delayed by risks, known or unknown, uncertainties, and various factors of any nature, notably related to economic, commercial or regulatory conjuncture, which occurrence could be likely to have a negative impact on future activity and performances of the Group.
This announcement does not constitute a public offering ('offre au public') nor an invitation to the public or to any qualified investor in connection with any offering. This announcement is not an offer of securities in the United States of America or in any other jurisdiction/country.
Attachment
2025.05.23 AGO - Press Release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Celanese Corp (CE) Q2 2025 Earnings Call Highlights: Strategic Moves Amid Market Challenges
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Celanese Corp (NYSE:CE) is focused on achieving a $2 per share quarterly EPS run rate through controllable actions such as cost structure improvements and executing differentiated business models. The company is prioritizing free cash flow generation, with a target of $700 million to $800 million for the year, translating to approximately $7 per share. Celanese Corp (NYSE:CE) is actively reducing inventory levels in the Engineered Materials segment through various strategies, including warehouse consolidation and SKU rationalization. The company is leveraging its low-cost production capabilities in the Western Hemisphere, particularly in the acetyls business, to maintain profitability despite challenging market conditions. Celanese Corp (NYSE:CE) is pursuing divestitures, such as the Micromax process, to strengthen its balance sheet and focus on core operations. Negative Points Order books have weakened, particularly in the China automotive sector and European demand, impacting the Engineered Materials segment. The company is experiencing volume weakness in the Western Hemisphere acetyl chain, which has continued into the third quarter. Celanese Corp (NYSE:CE) is facing challenges in achieving price increases in certain Engineered Materials products, with some pricing at unsustainable levels. The acetyls business is impacted by overcapacity in Asia, leading to lower third-party acetic acid sales and margin compression. Visibility on order books is limited, with short-term visibility in both acetyls and Engineered Materials segments, making it difficult to predict future demand accurately. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with CE. Q: Can you provide more color on the weakening order books you mentioned, particularly in which end markets this is occurring? A: Scott Richardson, President and CEO, explained that the weakening is primarily seen in China automotive orders and European demand within the Engineered Materials segment. The Americas have remained relatively stable, but there is also volume weakness in the Western Hemisphere's acetyl chain. Q: How do you plan to achieve the $2 per share quarterly EPS run rate, and when do you expect to reach it? A: Scott Richardson stated that the $2 target is achievable through concrete plans focusing on cost structure improvements and executing differentiated business models. The path includes inventory movement, cost actions, and price opportunities in Engineered Materials. The timeline may be delayed due to current demand conditions, but the company is prepared to capitalize on any demand changes. Q: What is the impact of the $25 million inventory reduction in the EM segment for Q3, and is it related to weaker demand? A: Scott Richardson and Chuck Kyrish, CFO, explained that the inventory reduction is part of a multiyear effort to operate with lower inventory levels. The $25 million impact is due to a mix of production campaigns and current demand trends, resulting in a sequential negative earnings impact for Q3. Q: Are tariffs in China affecting your tow business, and how is the VAM and acetic acid business performing in China? A: Scott Richardson confirmed that tariffs are not impacting the tow business as it operates through a joint venture in China. The VAM and acetic acid business is above breakeven, with a focus on downstream products for better value. Some US material is sold in Asia, either directly or through swaps. Q: How do you view the structural challenges in your businesses, and are there any long-term issues affecting earnings power? A: Scott Richardson expressed confidence in the company's actions to increase earnings power and readiness for demand changes. He highlighted cost structure improvements and strategic positioning in the Western Hemisphere as key factors. While some business areas face challenges, the company is focused on continuous improvement and adaptability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10 hours ago
- Business Insider
Jefferies Sticks to Its Hold Rating for Celanese (CE)
Jefferies analyst Laurence Alexander maintained a Hold rating on Celanese today and set a price target of $47.00. The company's shares closed today at $41.22. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alexander covers the Basic Materials sector, focusing on stocks such as MP Materials, Ashland, and Ecolab. According to TipRanks, Alexander has an average return of -2.1% and a 45.55% success rate on recommended stocks. In addition to Jefferies, Celanese also received a Hold from BMO Capital's John McNulty in a report issued today. However, on the same day, Wells Fargo maintained a Buy rating on Celanese (NYSE: CE). CE market cap is currently $5.19B and has a P/E ratio of -3.20. Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CE in relation to earlier this year. Most recently, in May 2025, Mark Christopher Murray, the SVP – Acetyls of CE bought 1,479.00 shares for a total of $77,174.22.
Business Wire
a day ago
- Business Wire
Minze Health Appoints Thomas Moore as President and Chief Executive Officer
ANTWERP, Belgium & MINNEAPOLIS--(BUSINESS WIRE)--Minze Health, a leader in digital diagnostics and therapeutics for urology, announced today that Thomas Moore has been appointed President and Chief Executive Officer, effective immediately. Moore brings over two decades of commercial leadership in medtech and a proven track record of driving growth, reimbursement, and global market expansion across the U.S. and Europe. Prior to joining Minze, Moore served as Chief Commercial Officer at GT Medical Technologies and executive leadership roles at Ablative Solutions and CVRx, where he played a central role in revitalizing trial enrollment, scaling commercial operations, and raising over $100M in venture funding. His leadership has accelerated pivotal clinical trials, launched novel therapies, and expanded reimbursement in key global markets. 'Minze is uniquely positioned to redefine the patient pathway for millions affected by BPH and OAB through our home-based diagnostics and evidence-backed therapeutics,' said Moore. 'I'm honored to join this world-class team and lead our expansion into the U.S. while advancing strategic partnerships, reimbursement access, and product innovation. The opportunity to make urologic care more accurate, efficient, and accessible has never been more urgent or exciting.' Moore's appointment marks a new chapter in Minze's growth trajectory, as the company prepares for commercial scaling, key reimbursement milestones, and Series B fundraising. 'Tom is the right leader at the right time,' said Steffen Hovard, Executive Chairman of the Board. 'He brings a powerful combination of strategic vision, commercial discipline, and passion for patient-centered innovation. We're thrilled to welcome him as CEO and confident he'll accelerate Minze's mission to become the global standard in digital urology care.' About Minze Health Minze Health is transforming urology by combining accurate at-home diagnostics, remote monitoring, and digital therapeutics into a single, scalable platform. With CE mark and 510(k) exemptions, Minze's ecosystem supports early diagnosis and personalized care for conditions like BPH and OAB—empowering patients and relieving pressure on overburdened urology systems. For more information, visit
